Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients

The therapeutic goal for hepatitis B virus (HBV) infection is HBs antigen (HBsAg) seroclearance, which is achieved through 48-week pegylated interferon (Peg-IFN) therapy. This study aimed to identify predictive biomarkers for sustained HBsAg reduction by analyzing serum microRNAs. Twenty-two consecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Koji, Mimura, Shima, Iwama, Hisakazu, Nakahara, Mai, Oura, Kyoko, Tadokoro, Tomoko, Nomura, Takako, Tani, Joji, Yoneyama, Hirohito, Morishita, Asahiro, Oryu, Makoto, Himoto, Takashi, Nishitsuji, Hironori, Shimotohno, Kunitada, Omata, Masao, Masaki, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073286/
https://www.ncbi.nlm.nih.gov/pubmed/30004437
http://dx.doi.org/10.3390/ijms19071940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073286/
https://www.ncbi.nlm.nih.gov/pubmed/30004437
http://dx.doi.org/10.3390/ijms19071940

Ejemplares similares